The Challenges of Recombinant Endostatin in Clinical Application: Focus on the Different Expression Systems and Molecular Bioengineering
Open Access
- 13 April 2017
- journal article
- review article
- Published by Maad Rayan Publishing Company in Advanced Pharmaceutical Bulletin
- Vol. 7 (1) , 21-34
Abstract
The Challenges of Recombinant Endostatin in Clinical Application: Focus on the Different Expression Systems and Molecular BioengineeringKeywords
This publication has 102 references indexed in Scilit:
- Co-delivery of docetaxel and endostatin by a biodegradable nanoparticle for the synergistic treatment of cervical cancerDiscover Nano, 2012
- Suitable carriers for encapsulation and distribution of endostar: comparison of endostar-loaded particulate carriersInternational Journal of Nanomedicine, 2011
- Inhibition of ovarian cancer by RGD‐P125A‐endostatin‐Fc fusion proteinsInternational Journal of Cancer, 2011
- Endostar-loaded PEG-PLGA nanoparticles: in vitro and in vivo evaluationInternational Journal of Nanomedicine, 2010
- The Role of Wnt Signaling in Physiological and Pathological AngiogenesisCirculation Research, 2010
- Endogenous Matrix-Derived Inhibitors of AngiogenesisPharmaceuticals, 2010
- High-level expression and purification of soluble recombinant FGF21 protein by SUMO fusion in Escherichia coliBMC Biotechnology, 2010
- Endostatin: Current concepts about its biological role and mechanisms of actionBiochemistry (Moscow), 2007
- Cellular Actions and Signaling by EndostatinCritical Reviews™ in Eukaryotic Gene Expression, 2002
- Crystal structure of the angiogenesis inhibitor endostatin at 1.5 Å resolutionThe EMBO Journal, 1998